Antibody, Immunoglobulin, Or Fragment Thereof Fused Via Peptide Linkage To Nonimmunoglobulin Protein, Polypeptide, Or Fragment Thereof (i.e., Antibody Or Immunoglobulin Fusion Protein Or Polypeptide) Patents (Class 424/134.1)
  • Patent number: 11318126
    Abstract: Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 3, 2022
    Assignee: Kyoto University
    Inventors: Masatoshi Hagiwara, Akiko Kobayashi, Takamitsu Hosoya, Suguru Yoshida, Yuto Sumida
  • Patent number: 11306147
    Abstract: The present invention relates to the field of biomedicine and antibody engineering. Specifically, it relates to mono and multispecific multivalent single chain polypeptide molecules and derivatives thereof, preferably to multispecific single chain (tandem) trimerbodies with defined stoichiometry, to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, use as diagnostics or imaging reagents and combination therapies using thereof.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 19, 2022
    Assignee: Leadartis, S.L.
    Inventors: Luis Álvarez Vallina, Laura Sanz Alcober
  • Patent number: 11306139
    Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 19, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11306146
    Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 19, 2022
    Assignee: Merck Patent GmbH
    Inventors: Josef Straub, Eike Staub
  • Patent number: 11299536
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 12, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Patent number: 11278546
    Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 22, 2022
    Assignee: AIVIVA BIOPHARMA, INC.
    Inventors: Diane Tang-Liu, Gerald Woodrow Devries, Tiffany Constance Liu
  • Patent number: 11274140
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 15, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • Patent number: 11274160
    Abstract: The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 15, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, INSTITUT JEAN PAOLI & IRENE CALETTES, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE
    Inventor: Marc Lopez
  • Patent number: 11273203
    Abstract: Methods and kits for mitigating a toxic effect of at least one of vesicants and caustic gases in a subject in need thereof are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the toxic effect of the vesicant or caustic gas.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 15, 2022
    Assignees: Janssen Pharmaceutica NV, Rutgers, The State University of New Jersey
    Inventors: Gary Eichenbaum, Edward John Yurkow
  • Patent number: 11267857
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Patent number: 11266689
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: March 8, 2022
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • Patent number: 11261252
    Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 11246882
    Abstract: A pharmaceutical composition includes an NAG-1 inhibitor as an active ingredient for inhibiting resistance against an anticancer drug of an ovarian cancer patient and a method of diagnosing prognosis of resistance against an anticancer drug of an ovarian cancer patient by using the NAG-1 inhibitor. It is found by controlling NAG-1 protein that NAG-1, which is overexpressed in an ovarian cancer patient and in an ovarian cancer stem cell having resistance against an anticancer drug, plays a key role in a chronic inflammatory reaction and resistance against an anticancer drug, and in this regard, NAG-1 can be used as a target gene for effective tumor therapy.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: February 15, 2022
    Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Yuseok Moon, Ki Hyung Kim
  • Patent number: 11241498
    Abstract: Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: February 8, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Xiaolin Tang, David Brett Ludwig
  • Patent number: 11242392
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: February 8, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Patent number: 11230588
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: January 25, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker, Mark F. Maurer, Joseph L. Kuijper
  • Patent number: 11229686
    Abstract: A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 25, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Rajendra Pradhan, Xiang Gao
  • Patent number: 11224637
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5?-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: January 18, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Scott Edward Moseley, Andrew E. Denker, Wei-Jian Pan
  • Patent number: 11219693
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drag selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drag-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: January 11, 2022
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-François Haeuw, Marie Lamothe
  • Patent number: 11213591
    Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 4, 2022
    Assignee: FUDAN UNIVERSITY
    Inventors: Gang Wei, Kuan Jiang, Weiyue Lu, Chang Liu, Lingyu Tai, Xin Gao
  • Patent number: 11213570
    Abstract: Methods for the treatment or prevention of disease, such as fatty liver disease and obesity, are described including the modulation the amount of CTRP1 in a subject. Novel mouse strains are also described.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 4, 2022
    Assignee: The Johns Hopkins University
    Inventors: Guang William Wong, Susana Rodriguez
  • Patent number: 11207389
    Abstract: The present invention relates to a composition for treatment or prevention of infectious inflammatory diseases comprising tryptophanyl-tRNA synthetase as an active ingredient, and a composition for immune enhancement. More specifically, the present invention relates to a pharmaceutical composition for treatment or prevention of infectious inflammatory diseasess comprising tryptophanyl-tRNA synthetase as an active ingredient, a food composition for preventing or improving, a veterinary composition for preventing or treating, and a composition for immune enhancement comprising a tryptophanyl-tRNA synthetase as an active ingredient, respectively. The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 28, 2021
    Assignee: MIRIMGENE CO., LTD.
    Inventors: Sunghoon Kim, Mi Rim Jin, Young Ha Ahn
  • Patent number: 11186820
    Abstract: The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: November 30, 2021
    Assignee: Procella Therapeutics AB
    Inventors: Kenneth R. Chien, Jonathan Clarke, Chuen Yan Leung
  • Patent number: 11174315
    Abstract: The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: November 16, 2021
    Assignee: MacroGenics, Inc.
    Inventors: James Vasselli, Jon Marc Wigginton, Ezio Bonvini, Scott Koenig
  • Patent number: 11161890
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 2, 2021
    Assignee: Altor Bioscience LLC.
    Inventor: Hing C. Wong
  • Patent number: 11161906
    Abstract: The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 2, 2021
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, James William West, Sherry Lynn La Porte, Bryan Allen Irving, Daniel Robert Hostetter, Chihunt Wong
  • Patent number: 11155574
    Abstract: The present disclosure involves optimized methods for production of hiologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 26, 2021
    Assignee: GLIKNIK INC.
    Inventors: David S. Block, Emmanuel Y. Mérigeon, Henrik Olsen
  • Patent number: 11136380
    Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 5, 2021
    Assignee: Duke University
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
  • Patent number: 11124568
    Abstract: The present invention relates to the use of anti-CD3 and anti-CD25 antibodies for the management and treatment of inflammatory diseases and psycho-immune disorders, such as depression, autism (ASD) and attention deficit/hyperactivity disorder (ADHD).
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: September 21, 2021
    Assignee: Vitruviae LLC
    Inventors: Mahiuddin Ahmed, Sonia Sequeira
  • Patent number: 11117948
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: September 14, 2021
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker, Mark F. Maurer, Joseph L. Kuijper
  • Patent number: 11111296
    Abstract: The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: September 7, 2021
    Assignees: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: David K. Thomas, Todd R. Golub
  • Patent number: 11112413
    Abstract: The present disclosure is directed to epitope-tagged antibodies, as well as methods of employing the epitope-tagged antibodies for detecting one or more targets in a biological sample, e.g. a tissue sample.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: September 7, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Michael Farrell, Antony Hubbard, Eric May, Lei Tang, Tsu-Shuen Tsao, Wenjun Zhang
  • Patent number: 11104715
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: August 31, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • Patent number: 11090373
    Abstract: Described herein are agents and methods for targeting antigen-specific B cells using engineered T cells, such as regulatory T cells or cytotoxic T cells, or bi-specific antibodies. The agents and methods can be used to reduce undesirable immune responses.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 17, 2021
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: David W. Scott, Yongchan Kim, Aihong Zhang
  • Patent number: 11084866
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 10, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Patent number: 11065306
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 20, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Kenji Fujita, Dawn Phillips
  • Patent number: 11059879
    Abstract: Chimeric antigen receptor (CAR) polypeptides are provided comprising an antigen binding domain; a hinge domain; a transmembrane domain and an intracellular signaling domain, wherein the CAR polypeptide binds to a target antigen and wherein the antigen binding domain comprises HCDR sequences from a first antibody that binds to the target antigen and LCDR sequences from a second antibody that binds to the target antigen. In certain aspects, the target antigen is CD123.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 13, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Radhika Thokala, Laurence J.N. Cooper, Simon Olivares
  • Patent number: 11059873
    Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: July 13, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
  • Patent number: 11058722
    Abstract: The present invention provides a chimeric antigen-receptor (CAR)-forming polypeptide comprising: (i) an antigen-binding domain; (ii) a coiled-coil spacer domain; (iii) a transmembrane domain; and (iv) an endodomain. The invention also provides a multimeric CAR formed by association of a plurality of CAR-forming polypeptides by virtue of association of their coiled-coil spacer domains.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 13, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba
  • Patent number: 11045544
    Abstract: In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 29, 2021
    Assignee: Omeros Corporation
    Inventors: W. Jason Cummings, Patrick Gray, Larry Tjoelker, Munehisa Yabuki
  • Patent number: 11041020
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis (PsA).
    Type: Grant
    Filed: July 20, 2019
    Date of Patent: June 22, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Diane D. Harrison, Elizabeth C. Hsia, Lee-Lian Kim, Kim Hung Lo
  • Patent number: 11026921
    Abstract: The present invention provides compositions and methods for treating cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 8, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: David Avigan, Jacalyn Rosenblatt, Donald Kufe
  • Patent number: 11028163
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: June 8, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Patent number: 11021538
    Abstract: A bispecific coupled antibody, a preparation method and an application thereof are provided. Specifically, an anti-CTLA-4 humanized single-chain antibody fragment (scFv) is provided, which has the advantages of high affinity and strong specificity. Using the anti-CTLA-4 antibody to construct a recombinant bispecific conjugated antibody (fusing a humanized anti-Her-2 full antibody (Trastuzumab) with anti-CTLA-4 human single-chain antibody (scFv, single-chain antibody fragment)) is capable of significantly enhancing the body's immune response and maintaining or enhancing the activation state of T cells.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: June 1, 2021
    Inventors: Zeling Cai, Yi Chen
  • Patent number: 11020453
    Abstract: The present invention relates to the role of the IGFBP3/TMEM219 axis in the onset of diabetes and the related use of IGFBP3/TMEM219 axis inhibitors for the treatment and/or prevention of diabetes. The invention also relates to a method to identify a subject at risk of developing Type 1 and/or Type 2 diabetes and relative kit.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: June 1, 2021
    Assignee: Ospedale San Raffaele Srl
    Inventors: Francesca D'Addio, Paolo Fiorina
  • Patent number: 11021694
    Abstract: The invention discloses immunoglobulin fusion proteins designed to bind both CD47 and a tumor cell antigen. The immunoglobulin fusion proteins include a SIRP? moiety that binds CD47 and an antigen binding site for a tumor cell antigen.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: June 1, 2021
    Assignee: Merck Patent GmbH
    Inventors: Kin-Ming Lo, Nora Zizlsperger, Aroop Sircar
  • Patent number: 11015215
    Abstract: Methods of glycoprotein production employing monosaccharides capable of producing a global increase in flux through the sialic acid pathway are provided.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: May 25, 2021
    Assignee: The Johns Hopkins University
    Inventors: Kevin J. Yarema, Udayanath Aich, Ruben T. Almaraz
  • Patent number: 11001627
    Abstract: A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 11, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Tsutomu Arakawa, Douglas Farrar
  • Patent number: 10988543
    Abstract: The composition of anti-TNFR2 antibodies are provided, as well as methods of their preparation and use. This includes methods for treating disorders associated with TNF and/or TNFR2, such as cancer.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: April 27, 2021
    Assignee: OPI VI—IP HOLDCO LLC
    Inventor: Peter Armstrong Thompson
  • Patent number: 10973878
    Abstract: The present invention provides a recombinant fusion protein containing an anti-PD-L1 antibody, with at least one paratope of the anti-PD-L1 antibody linked via a linker to an extracellular Ig-like domain of a signal-regulator protein (SIRP) at N-terminus of a heavy chain or a light chain, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47 and/or PD-L1 using the recombinant protein.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: April 13, 2021
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) CO., LTD.
    Inventors: Wenzhi Tian, Song Li